In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction

Experimental and Clinical Immunogenetics

Volumn 15, Issue 2, 1998, Pages 100-111

  Sonderbye, Lene ^a   Feng, Sandy ^b   Yacoubian, Shahan ^a   Buehler, Hans ^b   Ahsan, Nasimul ^a   Mulligan, Richard ^b   Langhoff, Erik ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Anti tumor immunity; Cytotoxic T lymphocyte response; Dendritic cell; Intracellular antigen; Transduction

Indexed keywords

BETA GALACTOSIDASE;

ADENOVIRUS; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE INDUCTION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; IMMUNOSTIMULATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 0031854971     PISSN: 02549670     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019060     Document Type: Article

References (56)

1. Steinman RM: The dendritic cell System and its role in immunogenicity. Annu Rev Immunol 1991;9: 271-296.
2. Langhoff E, Steinman RM: Clonal expansion of human T lymphocytes initiated by dendritic cells. J Exp Med 1989;169:315-320.
3. Young JW, Steinman RM: Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med 1990;171:1315-1332.
4. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cell, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
5. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
6. Lethe B, Van den Eynde B, Van Pel A, Corradin G, Boon T: Mouse tumor rejection antigens P815A and P815B: Two epitopes earned by a single peptide. Eur J Immunol 1992;22:2283-2288.
7. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
8. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
9. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
10. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1997;184:465-472.
11. Song W, Kong H-L, Carpenter H, Torii H, Granstein R, Rafii S, Moore MAS, Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-1256.
12. Sprecht JM, Wang G, Do MT, Lam JS, Royal RE, Reves ME, Rosenberg SA, Hwu P: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186: 1213-1221.
13. Romani N, Reider D, Heuer M, Ebner S, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-151.
14. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNF alpha. J Exp Med 1996;184:695-706.
15. Suss G, Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996;183:1789-1796.
16. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, Dupont B: The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 1992;90:229-237.
17. Van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells, and other cells. Curr Opin Immunol 1997;9-330-337
18. Carbone FR, Bevan MJ: Class 1-restricted processing and presentation of exogeneous cell-associated antigen in vivo. J Exp Med 1990; 171:377-387.
19. Crowley M, Inaba K, Witmer-Pack M, Steinman RM: The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol 1989;118:108-125.
20. Langhoff E, McElrath MJ, Bos HJ, Pruett J, Granelli-Piperno A, Cohn ZA: Most CD4 positive T cells from HIV-1-infected patients can undergo prolonged clonal expansion. J Clin Invest 1989;48:1637-1643.
21. Szabolcs P, Moore MAS, Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995;154:5851-5861.
22. Rosenzwajg M, Canque B, Gluckman JC: Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 1996;87:535-544.
23. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
24. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-261.
25. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
26. Santiago-Schwarz F, Belilos E, Diamond B, Carsons SE: TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leuk Biol 1992; 52:274-281.
27. Sonderbye L, Magerstadt R, Blatman RN, Preffer FI, Langhoff E: Selective expression of human fascin (p55) by dendritic leukocytes; in Riccardi-Castagnoli P (ed): Dendritic cells in fundamental and clinical immunol. London, Plenum, 1997, vol 3, pp 41-46.
28. Mosialos G, Birkenbach M, Ayehunie S, Matsumura F, Pinkus GS, Kieff E, Langhoff E: Circulating human dendritic cells differentially express high levels of a p55-kD actin-bundling protein. Am J Pathol 1996; 148:593-600.
29. Langhoff E, Kalland K-H, Haseltine WA: Early molecular replication of human immunodeficiency virus type 1 in cultured blood-derived T helper dendritic cells. J Clin Invest 1993;91:2721-2726.
30. Langhoff E, Terwillinger EF, Bos HJ, Kalland KH, Poznansky MC, Bacon OML, Haseltine WA: Replication of human immunodeficiency virus type 1 in primary dendritic cell cultures. Proc Natl Acad Sciences USA 1991;88-7998-8002.
31. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vectors through cre-lox recombination. J Virol 1997; 71:1842-1549.
32. Langhoff E, Jakobsen BK, Platz P, Ryder LP, Svejgaard A: The impact of low donor-specific MLR versus HLA-DR compatibility on kidnev graft survival. Transplantation 1985;39:18-31.
33. Gavin MA, Gilbert MJ, Riddell SR, Greenberg PD, Bevan MJ: Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol 1993;151,3971-3980.
34. Langhoff E, Ladefoged J: In vitro natural killer and killer cell functions in uremia. Int Arch Allergy Appl Imrnunol 1985;78;218-220.
35. Lampson LA, Lampson MA, Dunne AD: Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: Use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res 1993;53:176-182.
36. Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP: Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother 1995; 18:139-146.
37. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-4692.
38. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158: 3270-3276.
39. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP: Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bne marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-119.
40. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170: 101-110.
41. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-2926.
42. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
43. Yang Y, Li Q, Ertl HCJ, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015.
44. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A: Dendritic cells produce IL-12 and direct the development of THI cells from naive CD4+T cells. J Immunol 1995;154: 5071-5079.
45. Seder RA, Gazzinelli A, Sher A, Paul WE: Interleukin-12 acts directly on CD4+ T cells to enhance priming of interferon-gamma production and diminishes interleukin-4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188.
46. Houghton AN: Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994;180:1-4.
47. Flammand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-610.
48. Roth C, Rochlitz C, Kourilsky P: Immune response against tumors. Adv Immunol 1994;57:281-351.
49. Boon T, Cerottini JC, Van den Eynde B, Van der Brygge P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
50. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
51. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
52. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
53. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996;56:3763-3770.
54. Tobery TW, Siliciano RF: Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997;185:909-920.
55. Townsend ARM, Bastin J, Gould K, Brownlee GG: Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence. Nature 1986;324:575-577.
56. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G: Defective presentation to class I-restricted cytotoxic T lymphocytes in vacciniainfected cells is overcome by enhanced degradation of antigen. J Exp Med 1988;168:1211-1224.